Company intelligence / Profile preview

Shenogen Pharma Group

Beijing, Beijing Municipality/Province-level city or region as appropriate., Chinashenogen.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

The lead compound Icaritin has demonstrated clinical safety and efficacy in Phase II studies for advanced HBV-related hepatocellular carcinoma and has progressed to a Phase III trial. The company’s pipeline includes additional assets at various stages from discovery through late-stage clinical development targeting oncology indications with novel mechanisms of action.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesHerbal medicine-derived compounds (e.g., Icaritin)Oncolytic virusesAntibody-based biologics (including bispecific and trispecific antibodies)PROTACs (Proteolysis-targeting chimeras)
Industry: Biotech

Drug pipeline

3 assets

Icaritin

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborates extensively with key research institutions and business partners but no specific names provided in search results.

Beyond the preview

Go deeper on Shenogen Pharma Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenogen Pharma Group.

Explore the full profile